title: Luteal phase hyperprolactinemia during ovulation induction with human menopausal gonadotropins: incidence, recurrence, and effect on pregnancy rates.
abstract: Hyperprolactinemia may develop during ovulation induction with human menopausal gonadotropins and hCG (hMG/hCG). Because elevated serum prolactin (PRL) has several adverse effects on female reproductive function, this event has been implicated as a factor to explain the difference between ovulation and pregnancy rates in hMG/hCG treatment cycles. The incidence and severity of hyperprolactinemia in the luteal phase of hMG/hCG-stimulated cycles was investigated in a large series of patients. We analyzed 240 consecutive, ovulatory hMG/hCG cycles in 96 women from July 1984 to January 1986. All women had failed to conceive with clomiphene citrate, and had normal luteal phase PRL levels during unstimulated cycles. Daily serum total estrogens were determined during hMG administration. Serum progesterone and PRL were determined in the mid-luteal phase (7 days post-hCG administration). In 7.5% of the cycles, luteal phase PRL elevations were greater than 25 ng/mL. Only 2.5% of cycles had levels of PRL greater than 35 ng/mL. Hyperprolactinemia infrequently recurred in different cycles of the same patient (two of 16 patients, 12.5%). Cycles with hyperprolactinemia were found to have significantly higher preovulatory estrogen levels. Serum progesterone levels were not significantly decreased in cycles with elevated PRL. Pregnancy rates in cycles with and without hyperprolactinemia were similar (7.7 versus 11.1%, respectively; P greater than .05). We conclude that the development of luteal phase hyperprolactinemia during ovulation induction with hMG/hCG is an isolated event. High preovulatory estrogen levels may predispose to its development. Because hyperprolactinemia is uncommon and is usually mild, other factors must be responsible for the difference between ovulation and pregnancy rates using hMG/hCG.
authors.affiliation: Center for Fertility and Reproductive Endocrinology, Columbia Hospital for Women, Washington, DC.
authors.forename: P D
authors.initials: PD
authors.lastname: Tippet
authors.forename: J A
authors.initials: JA
authors.lastname: Simon
authors.forename: S M
authors.initials: SM
authors.lastname: Rifka
authors.forename: R J
authors.initials: RJ
authors.lastname: Falk
mesh_terms: D006063:Chorionic Gonadotropin / Q000627:therapeutic use; D004967:Estrogens / Q000097:blood; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced*; D008183:Luteal Phase; D008596:Menotropins / Q000009:adverse effects* / Q000627:therapeutic use; D010062:Ovulation Induction; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011388:Prolactin / Q000097:blood
chemical_list: D006063:Chorionic Gonadotropin; D004967:Estrogens; D011374:Progesterone; D008596:Menotropins; D011388:Prolactin